Presentation: The Biomarker of Sublingual Immune Therapy (WAO International Scientific Conference 2012)

Sunday, 9 December 2012

Hall 4 (HICC)

Masafumi Sakashita, MD , The Department of Otorhinolaryngology Head & Neck Surgery, University of Fukui, Fukui, Japan

Yoshimasa Imoto, MD , The Department of Otorhinolaryngology Head & Neck Surgery, University of Fukui, Fukui, Japan

Yoko Osawa

Noboru Takahashi

Seita Kubo

Hideyuki Yamamoto

Takechiyo Yamada

Shigeharu Fujieda , The Departments of Otorhinolaryngology Head & Neck Surgery, University of Fukui, Fukui, Japan

Background: Allergic rhinitis (AR) is recognized as a major health problem worldwide. Allergen-specific immunotherapy (SIT) is the only available treatment that can alter the natural course of allergic disease. Recent findings in experimental models of allergic rhinitis suggest that complement 3a and 5a regulate the development of maladaptive Th2 and Th17 immunity. We investigated the changes of C3a, C5a, IL-17a in the serum of patients treated by Sublingual immune therapy (SLIT).

Methods: Symptoms were recorded in the allergy diary. The total symptom medication scores were calculated based on each symptoms and medication. We measured the C3a, C5a, IL-17a levels in serum of the 20 identical subjects by ELISA during 5 years.

Results: C3a and IL-17a showed significant decrease year by year during 5 years (p < 0.01).

Conclusions: C3a and IL-17a can be objective biomarker for following up the patients of SLIT.

3007 The Biomarker of Sublingual Immune Therapy